Bionomics IPO Presentation Deck
Bionomics Outlook: Renewed Value-driving Trajectory
Bionomics
Bionomics
Diversified model with multiple potential value-driving clinical milestones expected in the next 4 - 6 quarters
alı
BNC210's novel rapid onset formulation granted Fast Track designation for acute treatment of SAD
Established clinical proof-of-concept¹; expect Phase 2 Study start by YE'21 & topline data YE'22
BNC210 Phase 2b ATTUNE PTSD study under way with Fast Track designation for 1H'23 topline data
Tablet formulation achieves exposure projected from pharmacometric analysis
Merck strategic partnership for treatment of cognitive impairment in Alzheimer's disease with two
compounds in clinical development
Diverse early-stage pipeline of partnering prospects targeting Kv and Nav ion channels for treatment of
schizophrenia and pain, respectively
31
Well-capitalized balance sheet driven by experienced leadership
SAD Social Awety Disorder
PTSD-Post-Traumatic Stress Disorder
Wise T. et ot, Bological Psychiatry 2020 (htte://del.org/10.1016/5 bltsych 2019. 12.013): Perki At of Transional Psychay 202T (htt://g/10.1038/541.398-020-01 14I-S)View entire presentation